{
  "id": "601c4e5e1cb411341a000021",
  "type": "yesno",
  "question": "Is cabergoline used for treatment of the Nelson's syndrome ?",
  "ideal_answer": "Yes, cabergoline has been shown to be effective for treatment of the Nelson's syndrome.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20702648",
    "http://www.ncbi.nlm.nih.gov/pubmed/10971110",
    "http://www.ncbi.nlm.nih.gov/pubmed/15557761",
    "http://www.ncbi.nlm.nih.gov/pubmed/26221547",
    "http://www.ncbi.nlm.nih.gov/pubmed/16845600",
    "http://www.ncbi.nlm.nih.gov/pubmed/16311416",
    "http://www.ncbi.nlm.nih.gov/pubmed/17574308",
    "http://www.ncbi.nlm.nih.gov/pubmed/10710275"
  ],
  "snippets": [
    {
      "text": "Due to a rapid regrowth of the tumour, the patient did not receive gamma-knife therapy and was treated with cabergoline and somatostatin analogue for some time. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26221547",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Identification of D(2) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702648",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " In our observation cabergoline at 2 mg per week seems to be efficient after a 3 and a half years follow-up, in accordance with some recent publications. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17574308",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical and biochemical stabilization of Nelson's syndrome with long-term low-dose cabergoline treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845600",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We report the results of long-term (6-year) treatment of Nelson's syndrome with the long-acting dopamine agonist, cabergoline, in a 55-year-old woman.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This case demonstrates that long-term cabergoline treatment may be efficient in patients with Nelson's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therefore, in addition to prolactinomas, targets of dopamine agonist therapy are somatotroph tumors, nonfunctioning pituitary tumors, corticotroph pituitary tumors, Nelson's syndrome, gonadotropinomas, and thyrotropin-secreting pituitary tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16311416",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nelson's syndrome: complete remission with cabergoline but not with bromocriptine or cyproheptadine treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557761",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The results obtained show for the first time that a long-term treatment with cabergoline also brings about a complete remission of Nelson's syndrome in the presence of a pituitary macroadenoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15557761",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Complete remission of Nelson's syndrome after 1-year treatment with cabergoline.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10710275",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this case report we demonstrated that treatment with the long-acting D2 receptor agonist cabergoline for 1 year induced normalization of plasma ACTH levels and disappearance of the pituitary tumor in a patient with Nelson's syndrome. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10710275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This case demonstrated that cabergoline treatment is able to induce the remission of Nelson's syndrome and may be a valid therapeutic alternative in this syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10710275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "However, some preliminary data suggest a potential use of cabergoline in combination with ketoconazole, or alone, in selected cases of Cushing's disease or Nelson's syndrome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10971110",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report the results of long-term (6-year) treatment of Nelson's syndrome with the long-acting dopamine agonist, cabergoline, in a 55-year-old woman. The",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16845600",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "actinomas. Identification of D(2) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's diseas",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702648",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In order to investigate on the direct effect played by cabergoline treatment on the remission of Nelson's syndrome, the treatment was withdrawn.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10710275",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "lactinomas. Identification of D(2) receptors in corticotroph tumors led to clinical trials of cabergoline therapy in limited cases of Nelson's syndrome, ectopic ACTH-secreting tumors, and recently Cushing's disease (CD).OBJECTIVE: To evaluate the long-term efficacy of cabergoline monotherapy in patients with CD.METHODS: Retrospective analysis of non-randomized clinical therapy with cabergoline in 30 patients with CD treated in academic cente",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702648",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}